---
title: "TCT 2024: TRISCEND II reports positive outcomes for tricuspid replacement system"
date: "2024-10-30T21:24:03.000Z"
publishedDate: "30 octobre 2024"
summary: "The Evoque (Edwards Lifesciences) tricuspid valve replacement system demonstrated superiority compared to medical therapy alone for the one-year primary endpoint of the TRISCEND II trial. TRISCEND II is a randomised controlled pivotal trial designed to study the Evoque system with optimal medical therapy (OMT) compared to OMT alone with 2:1 randomisation."
importance: ""
sourceUrl: "https://cardiovascularnews.com/tct-2024-triscend-ii-reports-positive-outcomes-for-tricuspid-replacement-system/"
tags: ["France", "Actualité", "Cardiovascular News — Latest"]
permalink: "/papers/2024-10-30-tct-2024-triscend-ii-reports-positive-outcomes-for-tricuspid-replacement-system"
imageUrl: "https://cardiovascularnews.com/wp-content/uploads/sites/14/2024/10/IMG_2427-scaled.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/tct-2024-triscend-ii-reports-positive-outcomes-for-tricuspid-replacement-system/"
---

![TCT 2024: TRISCEND II reports positive outcomes for tricuspid replacement system](https://cardiovascularnews.com/wp-content/uploads/sites/14/2024/10/IMG_2427-scaled.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/tct-2024-triscend-ii-reports-positive-outcomes-for-tricuspid-replacement-system/*

## L’essentiel

The Evoque (Edwards Lifesciences) tricuspid valve replacement system demonstrated superiority compared to medical therapy alone for the one-year primary endpoint of the TRISCEND II trial. TRISCEND II is a randomised controlled pivotal trial designed to study the Evoque system with optimal medical therapy (OMT) compared to OMT alone with 2:1 randomisation.

## Lien source

https://cardiovascularnews.com/tct-2024-triscend-ii-reports-positive-outcomes-for-tricuspid-replacement-system/
